Literature DB >> 16705367

Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions.

Gregory E Weitsman1, George Skliris, Kanyarat Ung, Baocheng Peng, Mamoun Younes, Peter H Watson, Leigh C Murphy.   

Abstract

Several different antibodies to total estrogen receptor (ER)beta, ERbeta1 and ERbeta2/cx have been tested and compared for their ability to immunoprecipitate ERbeta specific isoforms under chromatin immunoprecipitation conditions (ChIP). The rabbit polyclonal antibodies AP-ERbeta1 and AP-ERbeta2/cx, specific for ERbeta1 and ERbeta2/cx isoforms, respectively, were the most efficient for ChIP. The monoclonal antibody MCA1974/PPG5/10 was also able to ChIP ERbeta1, but less efficiently than AP-ERbeta1. All other antibodies tested were not suitable for ChIP analyses although most antibodies tested immunoprecipitated the appropriate ERbeta isoforms under standard conditions. To identify antibodies that can also be used to verify in-vivo expression profiles, a comparison of the antibodies to detect ERbeta isoforms by western blotting and immunohistochemistry was also undertaken. Under the tissue processing and autostaining conditions used at the Manitoba Breast Tumor Bank 385P/GC17, MCA1974/PPG5/10, Ab288/14C8 and MCA2279S/57/3 were found to be the best for IHC of ERbeta isoforms in human breast tissue biopsy sections, while Ab14021, AP-ERbeta1 and AP-ERbeta2/cx were best for western blot detection of ERbeta isoforms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705367     DOI: 10.1007/s10549-006-9229-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  22 in total

1.  Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.

Authors:  Sri Navaratnam; Georgios Skliris; Gefei Qing; Shantanu Banerji; Ketan Badiani; Dongsheng Tu; Penelope A Bradbury; Natasha B Leighl; Frances A Shepherd; Janet Nowatzki; Alain Demers; Leigh Murphy
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

2.  ERβ expression and breast cancer risk prediction for women with atypias.

Authors:  Tina J Hieken; Jodi M Carter; John R Hawse; Tanya L Hoskin; Melanie Bois; Marlene Frost; Lynn C Hartmann; Derek C Radisky; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

3.  The genome landscape of ERalpha- and ERbeta-binding DNA regions.

Authors:  Yawen Liu; Hui Gao; Troels Torben Marstrand; Anders Ström; Eivind Valen; Albin Sandelin; Jan-Ake Gustafsson; Karin Dahlman-Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-13       Impact factor: 11.205

Review 4.  Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Authors:  Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras
Journal:  Crit Rev Oncog       Date:  2015

5.  Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.

Authors:  John R Hawse; Jodi M Carter; Kirsten G M Aspros; Elizabeth S Bruinsma; Justin W Koepplin; Vivian Negron; Malayannan Subramaniam; James N Ingle; Karen L Rech; Matthew P Goetz
Journal:  Breast Cancer Res Treat       Date:  2019-09-30       Impact factor: 4.872

Review 6.  Estrogen receptor-beta and breast cancer: translating biology into clinical practice.

Authors:  Yuet-Kin Leung; Ming-Tsung Lee; Hung-Ming Lam; Pheruza Tarapore; Shuk-Mei Ho
Journal:  Steroids       Date:  2012-03-29       Impact factor: 2.668

7.  Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells.

Authors:  Laura Macpherson; Jason Matthews
Journal:  Cancer Lett       Date:  2010-09-16       Impact factor: 8.679

8.  Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.

Authors:  Bhuvaneswari Ramaswamy; Sarmila Majumder; Satavisha Roy; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Mamoun Younes; Charles L Shapiro; Tasneem Motiwala; Samson T Jacob
Journal:  Mol Endocrinol       Date:  2008-12-18

9.  Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma.

Authors:  Nuiki Iota Chantzi; Dina G Tiniakos; Marina Palaiologou; Nikolaos Goutas; Theodoros Filippidis; Stamatis D Vassilaros; Eugen Dhimolea; Dimitra J Mitsiou; Muichael N Alexis
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-02       Impact factor: 4.553

10.  The gad2 promoter is a transcriptional target of estrogen receptor (ER)alpha and ER beta: a unifying hypothesis to explain diverse effects of estradiol.

Authors:  Edward D Hudgens; Lan Ji; Clifford D Carpenter; Sandra L Petersen
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.